DAYBREAK Trial and EMANATE Trial
Phase 2 and 3 treatment studies with setmelanotide in patients with obesity and rare genetic defects in the MC4 receptor signaling pathway
The clinical project is being realized by the Helmholtz Institute for Metabolism, Obesity and Vascular Research (HI-MAG), the University of Leipzig and University of Leipzig Medical Centerl.
DAYBREAK Trial and EMANATE Trial
Phase 2 and 3 treatment studies with setmelanotide in patients with obesity and rare genetic defects in the MC4 receptor signaling pathway
The clinical project is being realized by the Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG), the University of Leipzig and the University of Leipzig Medical Center.
About the Study
What is the aim of this study?
In addition to the frequent multifactorial and polygenetic causes of obesity, there are also rare cases in which single gene mutations disrupt the hypothalamic control of satiety and thus lead to obesity. These patients often have extreme obesity and a lack of satiety since early childhood. Setmelanotide, a new drug that targets central satiety control through the MC4 receptor signaling pathway, has shown promising results in the first years of clinical experience and has already received initial approvals in the US and Europe. The Department of Pediatrics and Adolescent Medicine and the Department of Endocrinology at Leipzig University Hospital, under the direction of Prof. Körner and Prof. Blüher, are now able to offer treatment with setmelanotide as part of an international multicenter clinical trial for some of these rare genetic disorders from the age of 6 years onwards.
Are you interested?
Then get in contact with us!
Project Team:
